- Home
- MBC vs ODTX Comparison
MBC vs ODTX Comparison
Compare MBC & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBC | ODTX |
|---|---|---|
| Founded | 1954 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 875.1M |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MBC | ODTX |
|---|---|---|
| Price | $9.26 | $20.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 177.5K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,734,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $6.61 | $15.10 |
| 52 Week High | $14.22 | $23.03 |
Technical Indicators
Market Signals| Indicator | MBC | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 54.42 |
| Support Level | $7.78 | $15.10 |
| Resistance Level | $9.55 | N/A |
| Average True Range (ATR) | 0.45 | 1.70 |
| MACD | 0.06 | 0.19 |
| Stochastic Oscillator | 83.23 | 49.67 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About ODTX Odyssey Therapeutics Inc. Common Stock
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.